Cover Image

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Ryan Yanzhe Lim, Glenn Jun Kit Ho, Mirudhula Gnanavelou, Eunice Xiang‐Xuan Tan
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
by: Glenn Jun Kit Ho, et al.
Published: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
by: Xinglin Li, et al.
Published: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
by: Eunice Yewon Lee, et al.
Published: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
by: Luis Antonio Díaz, et al.
Published: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
by: Juan Macias, et al.
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Authors' reply
by: L. Aceituno, et al.
Published: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
by: Simone Chin, et al.
Published: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
by: Raj Vuppalanchi, et al.
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects. Authors' Reply
by: David Mehdi Asgher Niazi, et al.
Published: (2026)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
by: Jessica D. Lee, et al.
Published: (2025)

Letter: Gastroparesis in Lung Transplantation: Time to Reframe and Standardize Post‐Transplant Foregut Motility Evaluation: Authors' Reply
by: Mohamed H. Eldesouki, et al.
Published: (2026)

Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
by: Mohammad Saeid Rezaee‐Zavareh, et al.
Published: (2026)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
by: Terry Cheuk‐Fung Yip, et al.
Published: (2025)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
by: Landon Long Chan, et al.
Published: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
by: Raj Vuppalanchi, et al.
Published: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
by: Kaleb Tesfai, et al.
Published: (2026)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
by: Xing Bai, et al.
Published: (2025)

Letter Regarding ‘Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components’. Authors' Reply
by: Stefano Siboni, et al.
Published: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
by: Jee‐Fu Huang, et al.
Published: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
by: Isabel Carbery, et al.
Published: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
by: Ting Wang, et al.
Published: (2024)

Editorial: Extracellular Matrix Biomarkers Illuminate the Architecture of Portal Hypertension in End‐Stage Liver Disease—Authors' Reply
by: Mattias Mandorfer, et al.
Published: (2025)

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection. Authors' Reply
by: Sara Ellegaard Paaske, et al.
Published: (2026)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
by: Isabella Lurje, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
by: A. B. Fons, et al.
Published: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
by: Yee Hui Yeo, et al.
Published: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
by: Shintaro Akiyama, et al.
Published: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
by: J. M. Schattenberg, et al.
Published: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
by: Virginia Solitano, et al.
Published: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
by: Irene Spinelli, et al.
Published: (2025)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
by: Hong‐Li Liu, et al.
Published: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
by: Mei Chin Lim, et al.
Published: (2026)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)